Comparing the effects of white coat hypertension and sustained hypertension on mortality in a UK primary care setting.
OBJECTIVE
We examined all-cause mortality within a primary care setting in patients with white coat hypertension or sustained hypertension in whom blood pressure (BP) monitoring was indicated.


METHODS
This prospective multicenter study of ambulatory BP monitoring included 48 family practices in the county of Oxfordshire, United Kingdom. Mortality was compared for patients having white coat hypertension (mean of 3 clinic BP readings >140/90 mm Hg and daytime ambulatory readings< or =135/85 mm Hg) and patients having sustained hypertension (mean of 3 clinic readings >140/90 mm Hg and daytime ambulatory readings >135/85 mm Hg).


RESULTS
A routine primary care cohort consisting of 5,182 patients chosen to undergo ambulatory BP monitoring by their family physician was followed up for a median of 7.3 years (interquartile range, 5.8-8.9). There were 335 deaths (6.5%), corresponding to a mortality rate of 8.9 deaths (95% confidence interval [CI], 8.0-9.9) per 1,000 years of follow-up. Patients with white coat hypertension (n = 1,117) were more likely to be female and were on average younger than patients with sustained hypertension (n = 4,065). The unadjusted rate of all-cause mortality in patients with white coat hypertension was lower, at 4.4 deaths per 1,000 years of follow-up (95% CI, 3.1-6.0) than that in patients with sustained hypertension, at 10.2 deaths per 1,000 years of follow-up (95% CI, 9.1-11.4). This reduction in all-cause mortality was still clinically significant after adjustment for age, sex, smoking, use of antihypertensive medication, and practice-clustering effects (hazard ratio = 0.64; 95% CI, 0.42-0.97; P=.04).


CONCLUSIONS
White coat hypertension (elevation of clinic BP only) confers significantly less risk of death than sustained hypertension (elevation of both clinic and ambulatory BPs). Trials are now needed to evaluate the risk reduction achievable in patients who have white coat hypertension and are receiving BP-lowering therapy.
Dawes
Martin G
MG
Department of Family Medicine, McGill University, Montreal, Quebec, Canada. martin.dawes@mcgill.ca
Bartlett
Gillian
G
Coats
Andrew J
AJ
Juszczak
Edmund
E
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D018660:Blood Pressure Monitoring, Ambulatory; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care / Q000706:statistics & numerical data*; D011446:Prospective Studies; D018570:Risk Assessment; D017678:Sex Distribution; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D006113:United Kingdom / Q000453:epidemiology
D000959:Antihypertensive Agents
Arch Intern Med. 1993 Dec 27;153(24):2741-8
8257249
Eur Heart J. 2000 Oct;21(20):1714-8
11032699
JAMA. 1983 May 27;249(20):2792-8
6842787
S Afr Med J. 2000 Sep;90(9):898-904
11081143
Circulation. 2005 Apr 12;111(14):1777-83
15809377
Int J Epidemiol. 1986 Mar;15(1):122-5
3957533
J Hum Hypertens. 2005 Oct;19(10):801-7
15959536
Am J Hypertens. 1992 Feb;5(2):64-70
1550667
Lancet. 1990 Apr 7;335(8693):827-38
1969567
Hypertension. 1994 Dec;24(6):793-801
7995639
J Am Coll Cardiol. 2002 Mar 6;39(5):878-85
11869856
Am J Hypertens. 1999 Mar;12(3):251-9
10192226
Am Heart J. 1988 Oct;116(4):1118-23
3177187
J Am Board Fam Pract. 1998 Jul-Aug;11(4):252-8
9719346
J Hum Hypertens. 2003 Dec;17(12):811-7
14704724
J Cardiovasc Pharmacol. 1994;23 Suppl 5:S5-11
7609507
Br Med J (Clin Res Ed). 1985 Jul 13;291(6488):97-104
2861880
Br J Gen Pract. 2003 Jan;53(486):61-2
12564285
Arch Fam Med. 1995 Aug;4(8):691-6
7620599
JAMA. 1988 Jan 8;259(2):225-8
3336140
BMJ. 1996 Dec 14;313(7071):1535-41
8978234
Cardiovasc Drugs Ther. 1989 Jun;3 Suppl 1:303-11
2487802
Can J Cardiol. 2006 May 15;22(7):573-81
16755312
Hypertension. 1985 Mar-Apr;7(2):171-7
3156813
J Hypertens Suppl. 1989 May;7(3):S29-32
2668462
Am J Hypertens. 1993 Jun;6(6 Pt 2):207S-210S
8347320
Blood Press Monit. 2000 Aug;5(4):223-6
11035864
Am J Hypertens. 2005 Oct;18(10):1369-74
16202864
Lancet. 2002 Dec 14;360(9349):1903-13
12493255
Blood Press Monit. 2006 Jun;11(3):111-8
16702819
J Am Coll Cardiol. 2005 Aug 2;46(3):508-15
16053966
Clin Exp Hypertens. 1993 Mar;15(2):271-87
8467317
J Am Board Fam Pract. 2001 May-Jun;14(3):166-71
11355047
J Hypertens. 1997 Apr;15(4):357-64
9211170
Med Sci Monit. 2005 Sep;11(9):CR403-9
16127357
J R Soc Med. 1998 Jun;91(6):301-4
9771513
J Hum Hypertens. 2001 Oct;15(10):681-4
11607797
Chronobiol Int. 2001 Jan;18(1):85-98
11247116
J Hypertens. 2007 Aug;25(8):1554-64
17620947
J Hypertens. 1999 Feb;17(2):151-83
10067786
Am J Hypertens. 1991 Nov;4(11):890-6
1789952
Br Med J (Clin Res Ed). 1982 Oct 2;285(6346):919-23
6811068
Obstet Gynecol. 1991 Jan;77(1):152-5
1984216